New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 17, 2014
16:18 EDTAKRX, ACT, HITKActavis to purchase four marketed products from Akorn and Hi-Tech Pharmacal
Actavis (ACT) announced that it has entered into agreements with Akorn (Akrx) and Hi-Tech Pharmacal (HITK) to purchase four currently marketed products and one product under development for cash consideration. The closing of the purchase agreements are contingent upon the consummation of Akorn's acquisition of Hi-Tech. Financial terms of the agreements were not disclosed. The agreements include three products marketed under Abbreviated New Drug Applications and one product marketed under a New Drug Application: Lidocaine/Prilocaine Topical Cream. The agreements also include one product under development.
News For ACT;AKRX;HITK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 29, 2015
10:00 EDTAKRXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:17 EDTAKRXAkorn initiated with a Neutral at Nomura
Subscribe for More Information
September 28, 2015
07:13 EDTAKRXAkorn launches Myorisan 30 mg Capsules
Akorn announced that it has launched the recently-approved 30 mg strength of Myorisan. This launch further builds the Myorisan product portfolio that also includes 10 mg, 20 mg and 40 mg capsules.
September 25, 2015
08:00 EDTAKRXAkorn price target lowered to $41 from $50 at Leerink
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use